Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

Novo Nordisk's team in India is urging the company to launch its popular weight-loss drug, Wegovy, next year to stay ahead of ...

Defiance ETFs introduces NVOX, a leveraged ETF offering 2X exposure to Novo Nordisk's stock price movements, targeting the ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

In a closed-door meeting at Novo's Denmark headquarters about two months ago, the India team raised concerns that the company ...

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Novo and Lilly are both scaling up production as they vie for a dominant share of a weight-loss market that some analysts forecast could reach $150 billion a year in the next decade ...

Yet at the annual meeting of the Menopause Society earlier this fall, researchers presented new evidence that hormone therapy ...

Doctors say early obesity intervention can help prevent later health problems. But prescribing GLP-1s, such as Ozempic and ...